Cell Therapy News

A randomized phase 3 trial designed to evaluate rexlemestrocel-L for patients with advanced chronic heart failure failed to achieve its primary endpoint, according to topline data released by the agent’s manufacturer.

Ryan Cassaday, MD, associate professor at University of Washington & Fred Hutchinson Cancer Research Center and attending physician at Seattle Cancer Care Alliance, discussed emerging strategies and developments in HIV malignancies, CD-22 targeted CAR T-cells and other presentations at the ASH Annual Meeting and Exposition.

First-line therapy with axicabtagene ciloleucel induced an objective response in 85% of patients with high-risk large B-cell lymphoma, according to phase 2 study results presented at the virtual ASH Annual Meeting and Exposition.

Young patients with B-cell acute lymphoblastic leukemia had shorter RFS and EFS if they received blinatumomab before chimeric antigen receptor T-cell therapy, according to results presented at the virtual ASH Annual Meeting and Exposition.

Researchers successfully created a CAR T-cell construct to signal CD58 mutation or loss in patients with large B cell lymphomas, according to a presentation from the ASH Annual Meeting and Exposition.

Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition

New data suggest ibrutinib may be able to improve CAR T-cell production when administered before apheresis, according to a presentation at the ASH Annual Meeting and Exposition.

The FDA placed a clinical hold on a phase 1/phase 2 trial designed to evaluate BPX-601 — a chimeric antigen receptor T-cell therapy — followed by rimiducid for patients with previously treated metastatic pancreatic or prostate cancer.

Ryan Cassaday, MD, associate professor of hematology at University of Washington, discussed new platforms for cellular immunotherapy and the Devillier presentation of natural killer (NK) cells in a therapeutic setting presented at the ASH Annual Meeting and Exposition.

The use of gene-edited stem cells has shown early positive results among patients with sickle cell disease and transfusion-dependent beta-thalassemia, according to data presented at the virtual ASH Annual Meeting and Exposition.